Close Menu

stock rating

The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.

The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.

The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28. 

The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.

There were more winners than losers in the 2015 GWDN Index, but some lost big.

The bank downgraded Quidel's shares to market perform and trimmed its Q4 revenue forecast due to a mild flu season.

The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.

Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has initiated coverage of PerkinElmer with an Overweight rating and a $46 price target.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.